
Opinion|Videos|August 6, 2024
Recurrence and BCG Resistance in High-Risk NMIBC
Experts discuss the rate of recurrence following first-line BCG therapy.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What is the rate of recurrence following first-line BCG therapy? Can you also talk about the definition of BCG unresponsive bladder cancer and approximately how many patients with high-risk NMIBC may be unresponsive to BCG?
Advertisement
Related to this article

Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.

Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.

CG Oncology plans to submit a second biologics license application to the FDA for cretostimogene in BCG-unresponsive NMIBC by the end of March 2027

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
Advertisement
Advertisement
Trending on Urology Times
1
LIB-01 enters phase 2b development for erectile dysfunction
2
Jonathan Rosenberg, MD, reacts to FDA approval of durvalumab plus EV for MIBC
3
Treatment Targets, Formulations, and the Future of Testosterone
4
Rethinking Testosterone Therapy After the FDA Label Revisions
5



